explore -WSS

explore

author：focus 2025-09-28 01:31:49 - browse：2

BARCELONA, Spain — Some of the patients waiting in the oncology ward of a hospital here, with its green-tiled floor and white walls, had arrived for a newfangled remedy for blood cancers, what’s known as a CAR-T therapy.

The patients were not here for one of the brand-name medicines — a Kymriah or Yescarta — that have shown the power of these cell-based approaches and helped reap their makers hundreds of millions of dollars. Rather, they would be receiving a CAR-T brewed up right here at Hospital Clínic de Barcelona.

Under a special European policy, the CAR-T developed by the hospital’s experts had won regulatory approval in Spain and was reimbursed by the national health system like other authorized medications. The therapy provided another option for patients, all at a price of 89,000 euros ($97,000), roughly a third of the list prices of the CAR-T products from biopharma companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Ford recalls 870K F

knowledge

WSS

Curing rare childhood diseases will falter unless Congress steps up

Public health communication lessons from Covid

Cheap, fast test for Zika and dengue could cost just $1

The system is set up to fail children with medical complexity

The mammogram wars are not over

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

leisure time

explore

hotspot

Drug repurposing or repositioning? The language matters

Moderna says combo Covid

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

New report analyzes digital physical therapy solutions' effectiveness

Guidelines to prevent youth baseball injuries need more muscle

Biden announces an advanced cancer research initiative

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Medical leaders decry Supreme Court decision on affirmative action

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

focus

Coercive sterilizations revealed by STAT prompt outrage

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Will biotech layoffs continue through 2023?

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

NIH tests clinical research in primary care with $30 million program

Stephen Quake on the Chan Zuckerberg quest to conquer disease

knowledge

knowledge

hotspot

focus